Clinical Trial Update: Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of sacituzumab govitecan and bevacizumab in metastatic triple-negative breast cancer, with enrollment by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: YING FAN | Conditions: Advanced Breast Cancer | Phase 2 | Status: ENROLLING_BY_INVITATION